Alumis Inc. (NASDAQ:ALMS) Major Shareholder Buys $86,800.00 in Stock

Alumis Inc. (NASDAQ:ALMS) major shareholder Foresite Labs, Llc bought 20,000 shares of Alumis stock in a transaction that occurred on Tuesday, May 6th. The stock was bought at an average cost of $4.34 per share, for a total transaction of $86,800.00. Following the purchase, the insider now owns 4,247,670 shares in the company, valued at $18,434,887.80. This represents a 0.47 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Foresite Labs, Llc also recently made the following trade(s):

• On Friday, May 2nd, Foresite Labs, Llc purchased 25,000 shares of Alumis stock. The stock was bought at an average cost of $4.62 per share, with a total value of $115,500.00.

Alumis Price Performance

ALMS opened at $5.03 on Friday. Alumis Inc. has a 1 year low of $3.18 and a 1 year high of $13.53. The company’s 50 day simple moving average is $5.43 and its 200 day simple moving average is $7.21.

Hedge Funds Weigh In On Alumis

A number of hedge funds have recently made changes to their positions in the stock. Wells Fargo & Company MN increased its holdings in shares of Alumis by 77.1% during the 4th quarter. Wells Fargo & Company MN now owns 8,779 shares of the company’s stock worth $69,000 after buying an additional 3,823 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in Alumis during the fourth quarter valued at about $79,000. Marshall Wace LLP acquired a new stake in Alumis during the fourth quarter worth about $108,000. XTX Topco Ltd purchased a new position in shares of Alumis in the 4th quarter worth about $129,000. Finally, Rhumbline Advisers lifted its stake in shares of Alumis by 21.7% in the 1st quarter. Rhumbline Advisers now owns 16,543 shares of the company’s stock valued at $102,000 after purchasing an additional 2,949 shares in the last quarter.

Analyst Ratings Changes

A number of analysts recently commented on ALMS shares. Oppenheimer began coverage on Alumis in a research report on Thursday, January 30th. They set an “outperform” rating and a $32.00 price objective for the company. HC Wainwright reiterated a “buy” rating and set a $14.00 price target on shares of Alumis in a report on Wednesday, April 30th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Alumis in a research note on Thursday, March 20th. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $25.86.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.